Additionally, high IL-33 immunoreactivity in metastatic CRC tumor cells has been associated with shorter survival (37), confirming sST2 as a protective tumorigenesis factor by counteracting protumoral IL-33 effects such as angiogenesis induction and modification of tumor microenvironment (38). Here, IL33 is linked to colorectal carcinoma.